Abstract 3542
Background
Programmed cell death protein 6 (PDCD6) mediates apoptosis via p53 dependent and independent pathways and is implicated in many cancer hallmarks. A multi-omics analysis of colorectal cancer (CRC) cell lines identified PDCD6 as a candidate prognostic and predictive biomarker. PDCD6 is dysregulated in different cancers, but the role of PDCD6 in CRC is still poorly understood.
Methods
The clinicopathological data on 483 CRC patients treated at Mater Dei Hospital Malta between January 2008 and December 2011 were collated and tissue microarrays constructed in triplicate to represent central and peripheral tumour areas. PDCD6 protein expression was quantified by multiplex immunofluorescence (mIF; QuPath) along with fifteen other protein targets representing important cancer signalling and immune pathways. Expression of 770 genes was assessed using the NanoString nCounter® PanCancer Pathways Panel in a subset of 34 patients with low/high PDCD6 expression. Associations with clinicopathological parameters including disease-free survival and overall survival (OS) were calculated.
Results
Intra-tumoural PDCD6 protein expression was heterogeneous, having a higher expression at the tumour edge (p = 0.001). Invasive edge PDCD6 protein expression was significantly associated with TNM stage and tumour grade (p = 0.04 and <0.001, respectively), with lower PDCD6 expression in higher stage and poorly differentiated CRCs. PDCD6 expression was also associated with 5-year OS (p = 0.003), and higher PDCD6 expression revealed a trend towards longer OS. PDCD6 and Ki67 expression were negatively correlated (rs = - 0.192, p = 0.002). Low and high PDCD6 expressers showed differential gene expression in several other cancer pathways.
Conclusions
PDCD6 shows both inter- and intra-tumoural heterogeneity in CRC, with expression patterns consistent with a tumour suppressive function. Contrarily, wider literature suggests that PDCD6 might also have an intrinsic oncogenic role under certain circumstances, and further exploration of PDCD6 pleiotropism in CRC is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Romina Briffa.
Funding
REACH HIGH Scholars Programme Part-financed by the European Union, Operational Programme II; Cohesion Policy 2014-2020 "Investing in human capital to create more opportunities and promote the wellbeing of society.".
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2507 - KEYLYNK-010: Phase 3 Study of Pembrolizumab (pembro) Plus Olaparib (OLA) vs Enzalutamide (ENZA) or Abiraterone (ABI) in ENZA- or ABI-Pretreated Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Had Progression on Chemotherapy (CTx)
Presenter: Evan Yu
Session: Poster Display session 3
Resources:
Abstract
2944 - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastasic hormone-sensitive prostate cancer.
Presenter: Jose Arranz Arija
Session: Poster Display session 3
Resources:
Abstract
3535 - A phase 1 study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ben Tran
Session: Poster Display session 3
Resources:
Abstract
4951 - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer (EudraCT: 2018-002350-78, NCT03903835)
Presenter: Johan Lindberg
Session: Poster Display session 3
Resources:
Abstract
2892 - A phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
2427 - The Extended/Phase II Study of Safety And Tolerability Of Proxalutamide (GT0918) In Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone (Abi) Or Enzalutamide (Enza)
Presenter: Nicholas Vogelzang
Session: Poster Display session 3
Resources:
Abstract
3224 - Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer
Presenter: Marit Vermunt
Session: Poster Display session 3
Resources:
Abstract
3312 - A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy.
Presenter: Piet Dirix
Session: Poster Display session 3
Resources:
Abstract
2829 - Health-Related Quality of Life (HRQoL) and Updated Follow-Up From KEYNOTE-057: Phase 2 Study of Pembrolizumab (pembro) for Patients (pts) With High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG)
Presenter: Ronald de Wit
Session: Poster Display session 3
Resources:
Abstract
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract